Third FDA/Alzheimer’s Disease Allies Meeting

ACT-AD, together with the Alzheimer’s Foundation of America, and the Alzheimers Drug Discovery Foundation, hosted an FDA/Alzheimer’s Disease Allies Meeting to bring together researchers, clinicians, regulators, drug developers and advocacy groups to discuss challenges in recent Alzheimer’s disease drug development and explore novel approaches to improving the way in which Phase II trials for disease-modifying therapies are designed in the future.
View Agenda
View Transcript